重症新冠肺炎-话题@MedSci - williamhill asia

#重症新冠肺炎#

23篇内容 | 1472人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2181193, encodeId=8ff1218119356, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a> <a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a> <a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Critical Care Medicine：巴瑞替尼与c治疗重症新冠肺炎的疗效与不良反应, objectType=article, longId=808241, objectId=cba8808241a1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668025373131_4754896.webp, objectUrl=/article/show_article.do?id=cba8808241a1, replyNumber=0, likeNumber=78, createdTime=2024-01-13, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cba8808241a1, moduleTitle=Critical Care Medicine：巴瑞替尼与c治疗重症新冠肺炎的疗效与不良反应, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=cba8808241a1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1579690, encodeId=60d815e9690cf, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=JAMA：鼻插管高流量氧疗可降低重症新冠肺炎患者不良预后风险, objectType=article, longId=221738, objectId=0c78221e385f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c78221e385f, replyNumber=0, likeNumber=79, createdTime=2021-12-10, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c78221e385f, moduleTitle=JAMA：鼻插管高流量氧疗可降低重症新冠肺炎患者不良预后风险, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0c78221e385f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579689, encodeId=720715e9689f2, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, objectType=article, longId=219794, objectId=be3b219e94bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be3b219e94bc, replyNumber=0, likeNumber=77, createdTime=2021-11-06, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be3b219e94bc, moduleTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=be3b219e94bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579688, encodeId=cfa015e96884c, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=JAMA：卡那奴单抗可改善重症新冠肺炎住院患者预后, objectType=article, longId=214594, objectId=16e221459474, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16e221459474, replyNumber=0, likeNumber=87, createdTime=2021-07-23, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16e221459474, moduleTitle=JAMA：卡那奴单抗可改善重症新冠肺炎住院患者预后, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=16e221459474)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579687, encodeId=daf315e9687bd, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Lancet respirat med：IL-6受体抑制剂Sarilumab用于重症新冠肺炎患者的疗效, objectType=article, longId=208244, objectId=5ca1208244b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ca1208244b3, replyNumber=0, likeNumber=69, createdTime=2021-03-12, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ca1208244b3, moduleTitle=Lancet respirat med：IL-6受体抑制剂Sarilumab用于重症新冠肺炎患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5ca1208244b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579686, encodeId=468115e968665, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Clin Transl Med：这也可以？月经血来源间充质干细胞可有效治疗重症新冠肺炎！, objectType=article, longId=207786, objectId=a7e520e786b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7e520e786b5, replyNumber=0, likeNumber=60, createdTime=2021-03-03, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7e520e786b5, moduleTitle=Clin Transl Med：这也可以？月经血来源间充质干细胞可有效治疗重症新冠肺炎！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a7e520e786b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579685, encodeId=2b5415e9685e2, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=NEJM：反转！白介素-6受体拮抗剂可改善危重症新冠肺炎患者预后！, objectType=article, longId=207688, objectId=9db020e68829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9db020e68829, replyNumber=0, likeNumber=82, createdTime=2021-02-28, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9db020e68829, moduleTitle=NEJM：反转！白介素-6受体拮抗剂可改善危重症新冠肺炎患者预后！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9db020e68829)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579684, encodeId=cdc615e96844e, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=NEJM：抗IL-6R抗体Tocilizumab治疗是否可改善重症新冠肺炎患者预后？, objectType=article, longId=207684, objectId=164820e684f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=164820e684f0, replyNumber=0, likeNumber=62, createdTime=2021-02-28, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=164820e684f0, moduleTitle=NEJM：抗IL-6R抗体Tocilizumab治疗是否可改善重症新冠肺炎患者预后？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=164820e684f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579683, encodeId=3f3e15e968315, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Circulation：重症新冠肺炎患者的心肌损伤风险及相关临床因素, objectType=article, longId=207123, objectId=979220e123a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979220e123a6, replyNumber=0, likeNumber=61, createdTime=2021-02-16, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979220e123a6, moduleTitle=Circulation：重症新冠肺炎患者的心肌损伤风险及相关临床因素, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=979220e123a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579682, encodeId=06be15e968230, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Lancet Rheumato：重症新冠肺炎 | 白介素抑制可用，但不能都用！, objectType=article, longId=206838, objectId=7aed206838d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7aed206838d4, replyNumber=0, likeNumber=75, createdTime=2021-02-07, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7aed206838d4, moduleTitle=Lancet Rheumato：重症新冠肺炎 | 白介素抑制可用，但不能都用！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7aed206838d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579681, encodeId=85b915e968123, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Lancet respir med：减少苯二氮卓类药物镇静，增加探视可降低重症新冠肺炎患者谵妄风险, objectType=article, longId=205540, objectId=3ff320554058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff320554058, replyNumber=0, likeNumber=78, createdTime=2021-01-11, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff320554058, moduleTitle=Lancet respir med：减少苯二氮卓类药物镇静，增加探视可降低重症新冠肺炎患者谵妄风险, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3ff320554058)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579680, encodeId=d0ab15e968075, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Lancet Rheumato：Vilobelimab可降低重症新冠肺炎患者死亡风险, objectType=article, longId=201392, objectId=c5662013928d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5662013928d, replyNumber=0, likeNumber=72, createdTime=2020-10-01, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5662013928d, moduleTitle=Lancet Rheumato：Vilobelimab可降低重症新冠肺炎患者死亡风险, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c5662013928d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579679, encodeId=3e2515e9679fe, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=JAMA：氢化可的松对重症新冠肺炎患者器官支持治疗天数的影响, objectType=article, longId=200445, objectId=a98520044518, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a98520044518, replyNumber=0, likeNumber=58, createdTime=2020-09-10, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a98520044518, moduleTitle=JAMA：氢化可的松对重症新冠肺炎患者器官支持治疗天数的影响, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a98520044518)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579678, encodeId=dd6915e9678fe, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=JAMA：地塞米松治可减少重症新冠肺炎患者呼吸机使用天数, objectType=article, longId=200443, objectId=48de2004439a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48de2004439a, replyNumber=0, likeNumber=54, createdTime=2020-09-10, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48de2004439a, moduleTitle=JAMA：地塞米松治可减少重症新冠肺炎患者呼吸机使用天数, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=48de2004439a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579677, encodeId=9ed115e9677b3, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle= JAMA Intern Med：与重症新冠肺炎患者死亡相关的人口统计学、临床和医院因素研究, objectType=article, longId=197885, objectId=871719e88534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=871719e88534, replyNumber=0, likeNumber=76, createdTime=2020-07-23, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=871719e88534, moduleTitle= JAMA Intern Med：与重症新冠肺炎患者死亡相关的人口统计学、临床和医院因素研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=871719e88534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579676, encodeId=0c7f15e9676be, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Ann Rheum Dis：重症新冠肺炎炎症风暴使用sarilumab阻断白介素-6的疗效, objectType=article, longId=197867, objectId=26d719e867cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26d719e867cc, replyNumber=0, likeNumber=52, createdTime=2020-07-23, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26d719e867cc, moduleTitle=Ann Rheum Dis：重症新冠肺炎炎症风暴使用sarilumab阻断白介素-6的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=26d719e867cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579675, encodeId=c89315e9675e2, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Sci Immun：IFN-1有望成为治疗重症新冠肺炎的“靶点新星”, objectType=article, longId=197847, objectId=f34519e84740, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f34519e84740, replyNumber=0, likeNumber=159, createdTime=2020-07-22, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f34519e84740, moduleTitle=Sci Immun：IFN-1有望成为治疗重症新冠肺炎的“靶点新星”, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f34519e84740)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579674, encodeId=b6c415e967412, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Lancet Rheumato：Anakinra治疗重症新冠肺炎患者, objectType=article, longId=195185, objectId=262d19518599, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262d19518599, replyNumber=0, likeNumber=66, createdTime=2020-06-04, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262d19518599, moduleTitle=Lancet Rheumato：Anakinra治疗重症新冠肺炎患者, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=262d19518599)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579673, encodeId=ef2f15e9673b8, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=重症新冠肺炎患者应用瑞德昔韦有获益！新英格兰医学杂志研究：需谨慎对待，不能过早乐观, objectType=article, longId=192241, objectId=8e8a19224155, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e8a19224155, replyNumber=0, likeNumber=69, createdTime=2020-04-16, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e8a19224155, moduleTitle=重症新冠肺炎患者应用瑞德昔韦有获益！新英格兰医学杂志研究：需谨慎对待，不能过早乐观, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=8e8a19224155)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579672, encodeId=787115e967208, content=<a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=NEJM：重症新冠肺炎患者应用瑞德昔韦有获益！, objectType=article, longId=192109, objectId=1449192109a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1449192109a5, replyNumber=0, likeNumber=68, createdTime=2020-04-14, rootId=0, userName=ms5439512287675881, userId=9f4216549541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1449192109a5, moduleTitle=NEJM：重症新冠肺炎患者应用瑞德昔韦有获益！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1449192109a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

重症新冠肺炎

2020-05-29

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#巴瑞替尼# #新冠肺炎# #重症新冠肺炎#

Critical Care Medicine：巴瑞替尼与c治疗重症新冠肺炎的疗效与不良反应

2024-01-13发表于上海

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

JAMA：鼻插管高流量氧疗可降低重症新冠肺炎患者不良预后风险

2021-12-10

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%

2021-11-06

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

JAMA：卡那奴单抗可改善重症新冠肺炎住院患者预后

2021-07-23

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

Lancet respirat med：IL-6受体抑制剂Sarilumab用于重症新冠肺炎患者的疗效

2021-03-12

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

Clin Transl Med：这也可以？月经血来源间充质干细胞可有效治疗重症新冠肺炎！

2021-03-03

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

NEJM：反转！白介素-6受体拮抗剂可改善危重症新冠肺炎患者预后！

2021-02-28

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

NEJM：抗IL-6R抗体Tocilizumab治疗是否可改善重症新冠肺炎患者预后？

2021-02-28

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

Circulation：重症新冠肺炎患者的心肌损伤风险及相关临床因素

2021-02-16

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

Lancet Rheumato：重症新冠肺炎 | 白介素抑制可用，但不能都用！

2021-02-07

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

Lancet respir med：减少苯二氮卓类药物镇静，增加探视可降低重症新冠肺炎患者谵妄风险

2021-01-11

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

Lancet Rheumato：Vilobelimab可降低重症新冠肺炎患者死亡风险

2020-10-01

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

JAMA：氢化可的松对重症新冠肺炎患者器官支持治疗天数的影响

2020-09-10

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

JAMA：地塞米松治可减少重症新冠肺炎患者呼吸机使用天数

2020-09-10

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

JAMA Intern Med：与重症新冠肺炎患者死亡相关的人口统计学、临床和医院因素研究

2020-07-23

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

Ann Rheum Dis：重症新冠肺炎炎症风暴使用sarilumab阻断白介素-6的疗效

2020-07-23

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

Sci Immun：IFN-1有望成为治疗重症新冠肺炎的“靶点新星”

2020-07-22

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

Lancet Rheumato：Anakinra治疗重症新冠肺炎患者

2020-06-04

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

重症新冠肺炎患者应用瑞德昔韦有获益！新英格兰医学杂志研究：需谨慎对待，不能过早乐观

2020-04-16

ms5439512287675881 (审核中...)

前往app查看评论内容

#重症新冠肺炎#

NEJM：重症新冠肺炎患者应用瑞德昔韦有获益！

2020-04-14

科室
- - 订阅+
  - 更多科室
工具
服务